Product Information
MS CONTIN ER 30 MG TABLET is a brand product labeled by Rhodes Pharmaceuticals L.P., priced at $8.9478 per EA under NDC 42858063101. Its NADAC has been published 174 times since Jul 12, 2017.
FDA first approved this application on May 29, 1987. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
30 mg/1
Manufacturer
Rhodes Pharmaceuticals L.P.NDC
42858063101
Classification
Brand
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
MORPHINE SULFATEApproval Type
New Drug (NDA)
FDA Application
NDA019516FDA Approved
5/29/1987
TE Code
AB
On Market Since
5/15/2017
Pharmacological Classes
Price Statistics
The NADAC for MS CONTIN ER 30 MG TABLET has been published 174 times since Jul 12, 2017, and over the history we have for it it has risen 33.2%. The table below summarizes its recorded NADAC range and movement.
| Current price | $8.9478 per EA |
|---|---|
| All-time high | $8.9663 (Jun 10, 2026) |
| All-time low | $6.7158 (Jul 12, 2017) |
| 52-week high | $8.9663 |
| 52-week low | $8.8798 |
| Median price | $8.3803 |
| Average price | $8.1111 |
| Largest weekly change | +14.5% (Apr 17, 2024) |
| Weeks tracked | 174 |
| Tracking since | Jul 12, 2017 |
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 96% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Rhodes Pharmaceuticals L.P. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
morphine sulfate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Opioid Agonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of MS CONTIN ER 30 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for MS CONTIN ER 30 MG TABLET, manufactured by Rhodes Pharmaceuticals L.P., is $8.9478 per EA (NDC 42858063101), effective Sep 30, 2026.
How has the price of MS CONTIN ER 30 MG TABLET changed over time?
Over the history we have for it, the NADAC for MS CONTIN ER 30 MG TABLET has risen 33.2%. It has been tracked across 174 weekly CMS publications since Jul 12, 2017.
What are the highest and lowest recorded NADAC prices for MS CONTIN ER 30 MG TABLET?
Since Jul 12, 2017, the NADAC for MS CONTIN ER 30 MG TABLET has ranged from a low of $6.7158 (Jul 12, 2017) to a high of $8.9663 (Jun 10, 2026), with a median of $8.3803 per EA.
Are there cheaper alternatives to MS CONTIN ER 30 MG TABLET?
Yes. 2 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, MORPHINE SULFATE IR 30 MG TAB, is $0.3414 per EA — about 96% below MS CONTIN ER 30 MG TABLET.
Who manufactures MS CONTIN ER 30 MG TABLET?
MS CONTIN ER 30 MG TABLET (NDC 42858063101) is labeled by Rhodes Pharmaceuticals L.P., and CMS classifies it as a brand product.